GLPG 0555

Drug Profile

GLPG 0555

Alternative Names: GLPG 555; GLPG0555

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Galapagos NV
  • Developer Galapagos NV; GlaxoSmithKline
  • Class Disease-modifying antirheumatics; Small molecules
  • Mechanism of Action Protein kinase modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Osteoarthritis

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Osteoarthritis(In volunteers) in Belgium (PO, Capsule)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Osteoarthritis(In volunteers) in Belgium (PO, Liquid)
  • 21 Feb 2012 GLPG 0555 licensed to GlaxoSmithKline
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top